Financhill
Sell
26

IRWD Quote, Financials, Valuation and Earnings

Last price:
$0.93
Seasonality move :
1.72%
Day range:
$0.90 - $0.98
52-week range:
$0.59 - $8.45
Dividend yield:
0%
P/E ratio:
126.50x
P/S ratio:
0.43x
P/B ratio:
--
Volume:
2M
Avg. volume:
3.9M
1-year change:
-88.77%
Market cap:
$150.9M
Revenue:
$351.4M
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IRWD
Ironwood Pharmaceuticals
$59.9M -$0.05 -10.49% -55.57% $3.36
ABBV
AbbVie
$12.9B $2.40 3.27% 312.3% $210.68
AMGN
Amgen
$8B $4.26 5.56% 282.31% $313.62
BMY
Bristol-Myers Squibb
$10.7B $1.50 -7.24% 102.38% $57.20
LLY
Eli Lilly and
$12.7B $3.46 26.45% 67.04% $981.63
PFE
Pfizer
$14.1B $0.67 1.01% 5619.6% $29.25
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IRWD
Ironwood Pharmaceuticals
$0.93 $3.36 $150.9M 126.50x $0.00 0% 0.43x
ABBV
AbbVie
$198.47 $210.68 $351.1B 84.46x $1.64 3.22% 6.13x
AMGN
Amgen
$281.22 $313.62 $151.2B 25.66x $2.38 3.25% 4.46x
BMY
Bristol-Myers Squibb
$50.57 $57.20 $102.9B 18.94x $0.62 4.83% 2.16x
LLY
Eli Lilly and
$823.62 $981.63 $739.6B 67.02x $1.50 0.66% 15.18x
PFE
Pfizer
$24.20 $29.25 $137.2B 17.54x $0.43 6.98% 2.21x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IRWD
Ironwood Pharmaceuticals
206.54% -1.225 82.38% 4.35x
ABBV
AbbVie
95.28% -0.326 -- 0.43x
AMGN
Amgen
90.24% 0.239 34.26% 0.74x
BMY
Bristol-Myers Squibb
74.09% 0.332 41.04% 1.10x
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
PFE
Pfizer
41.92% 0.423 -- 0.82x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IRWD
Ironwood Pharmaceuticals
-- $33.3M 0.58% -- 37.55% $9.9M
ABBV
AbbVie
$9.3B $4B 5.46% 61.64% 17.15% $6.8B
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
BMY
Bristol-Myers Squibb
$8.2B $3.5B 7.93% 32.01% 30.94% $1.7B
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B
PFE
Pfizer
$10.9B $4.4B 5.01% 8.91% 25.08% $5.8B

Ironwood Pharmaceuticals vs. Competitors

  • Which has Higher Returns IRWD or ABBV?

    AbbVie has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 9.64%. Ironwood Pharmaceuticals's return on equity of -- beat AbbVie's return on equity of 61.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRWD
    Ironwood Pharmaceuticals
    -- $0.02 $282.7M
    ABBV
    AbbVie
    70.01% $0.72 $70.5B
  • What do Analysts Say About IRWD or ABBV?

    Ironwood Pharmaceuticals has a consensus price target of $3.36, signalling upside risk potential of 260.4%. On the other hand AbbVie has an analysts' consensus of $210.68 which suggests that it could grow by 6.15%. Given that Ironwood Pharmaceuticals has higher upside potential than AbbVie, analysts believe Ironwood Pharmaceuticals is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRWD
    Ironwood Pharmaceuticals
    0 5 0
    ABBV
    AbbVie
    13 11 0
  • Is IRWD or ABBV More Risky?

    Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison AbbVie has a beta of 0.557, suggesting its less volatile than the S&P 500 by 44.281%.

  • Which is a Better Dividend Stock IRWD or ABBV?

    Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.22% to investors and pays a quarterly dividend of $1.64 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. AbbVie pays out 257.71% of its earnings as a dividend.

  • Which has Better Financial Ratios IRWD or ABBV?

    Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than AbbVie quarterly revenues of $13.3B. Ironwood Pharmaceuticals's net income of $3.2M is lower than AbbVie's net income of $1.3B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while AbbVie's PE ratio is 84.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.43x versus 6.13x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRWD
    Ironwood Pharmaceuticals
    0.43x 126.50x $90.5M $3.2M
    ABBV
    AbbVie
    6.13x 84.46x $13.3B $1.3B
  • Which has Higher Returns IRWD or AMGN?

    Amgen has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 21.23%. Ironwood Pharmaceuticals's return on equity of -- beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRWD
    Ironwood Pharmaceuticals
    -- $0.02 $282.7M
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About IRWD or AMGN?

    Ironwood Pharmaceuticals has a consensus price target of $3.36, signalling upside risk potential of 260.4%. On the other hand Amgen has an analysts' consensus of $313.62 which suggests that it could grow by 11.52%. Given that Ironwood Pharmaceuticals has higher upside potential than Amgen, analysts believe Ironwood Pharmaceuticals is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRWD
    Ironwood Pharmaceuticals
    0 5 0
    AMGN
    Amgen
    9 15 2
  • Is IRWD or AMGN More Risky?

    Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

  • Which is a Better Dividend Stock IRWD or AMGN?

    Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.25% to investors and pays a quarterly dividend of $2.38 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios IRWD or AMGN?

    Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Amgen quarterly revenues of $8.1B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Amgen's net income of $1.7B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Amgen's PE ratio is 25.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.43x versus 4.46x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRWD
    Ironwood Pharmaceuticals
    0.43x 126.50x $90.5M $3.2M
    AMGN
    Amgen
    4.46x 25.66x $8.1B $1.7B
  • Which has Higher Returns IRWD or BMY?

    Bristol-Myers Squibb has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 21.93%. Ironwood Pharmaceuticals's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRWD
    Ironwood Pharmaceuticals
    -- $0.02 $282.7M
    BMY
    Bristol-Myers Squibb
    72.92% $1.20 $67.2B
  • What do Analysts Say About IRWD or BMY?

    Ironwood Pharmaceuticals has a consensus price target of $3.36, signalling upside risk potential of 260.4%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.20 which suggests that it could grow by 13.12%. Given that Ironwood Pharmaceuticals has higher upside potential than Bristol-Myers Squibb, analysts believe Ironwood Pharmaceuticals is more attractive than Bristol-Myers Squibb.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRWD
    Ironwood Pharmaceuticals
    0 5 0
    BMY
    Bristol-Myers Squibb
    3 18 1
  • Is IRWD or BMY More Risky?

    Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.827%.

  • Which is a Better Dividend Stock IRWD or BMY?

    Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.83% to investors and pays a quarterly dividend of $0.62 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

  • Which has Better Financial Ratios IRWD or BMY?

    Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Bristol-Myers Squibb's PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.43x versus 2.16x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRWD
    Ironwood Pharmaceuticals
    0.43x 126.50x $90.5M $3.2M
    BMY
    Bristol-Myers Squibb
    2.16x 18.94x $11.2B $2.5B
  • Which has Higher Returns IRWD or LLY?

    Eli Lilly and has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 21.68%. Ironwood Pharmaceuticals's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRWD
    Ironwood Pharmaceuticals
    -- $0.02 $282.7M
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About IRWD or LLY?

    Ironwood Pharmaceuticals has a consensus price target of $3.36, signalling upside risk potential of 260.4%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 19.18%. Given that Ironwood Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Ironwood Pharmaceuticals is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRWD
    Ironwood Pharmaceuticals
    0 5 0
    LLY
    Eli Lilly and
    15 3 1
  • Is IRWD or LLY More Risky?

    Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

  • Which is a Better Dividend Stock IRWD or LLY?

    Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IRWD or LLY?

    Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Eli Lilly and's net income of $2.8B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Eli Lilly and's PE ratio is 67.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.43x versus 15.18x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRWD
    Ironwood Pharmaceuticals
    0.43x 126.50x $90.5M $3.2M
    LLY
    Eli Lilly and
    15.18x 67.02x $12.7B $2.8B
  • Which has Higher Returns IRWD or PFE?

    Pfizer has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 21.63%. Ironwood Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRWD
    Ironwood Pharmaceuticals
    -- $0.02 $282.7M
    PFE
    Pfizer
    79.26% $0.52 $152.1B
  • What do Analysts Say About IRWD or PFE?

    Ironwood Pharmaceuticals has a consensus price target of $3.36, signalling upside risk potential of 260.4%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 20.86%. Given that Ironwood Pharmaceuticals has higher upside potential than Pfizer, analysts believe Ironwood Pharmaceuticals is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRWD
    Ironwood Pharmaceuticals
    0 5 0
    PFE
    Pfizer
    6 15 1
  • Is IRWD or PFE More Risky?

    Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

  • Which is a Better Dividend Stock IRWD or PFE?

    Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.98% to investors and pays a quarterly dividend of $0.43 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios IRWD or PFE?

    Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Pfizer quarterly revenues of $13.7B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Pfizer's net income of $3B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Pfizer's PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.43x versus 2.21x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRWD
    Ironwood Pharmaceuticals
    0.43x 126.50x $90.5M $3.2M
    PFE
    Pfizer
    2.21x 17.54x $13.7B $3B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Cathie Wood Buy AMD?
Why Did Cathie Wood Buy AMD?

Noted tech investor Cathie Wood has used the recent stock…

Why Did Salesforce Stock Drop After a Strong Quarter?
Why Did Salesforce Stock Drop After a Strong Quarter?

Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
4
CABO alert for May 3

Cable One [CABO] is down 41.98% over the past day.

Buy
55
PDEX alert for May 3

Pro-Dex [PDEX] is down 32.02% over the past day.

Buy
91
TRUP alert for May 3

Trupanion [TRUP] is up 23.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock